PAMELA B DAVIS, MD
Medical Practice at Euclid Ave, Cleveland, OH

6261787, Jul 17, 2001

Mar 8, 1999

9/264032

Pamela B. Davis - Cleveland heights OH
Thomas W. Ferkol - Concord OH
Elizabeth Eckman - Ponte Vedra Beach FL

Case Western Reserve University - Cleveland OH

G01N 3353, G01N 33567, C07K 1600, A61K 3800, C07H 2102

435 71

A bifunctional molecule consisting of a therapeutic molecule and a ligand which specifically binds a transcytotic receptor can be transported specifically from the basolateral surface of epithelial cells to the apical surface. This approach provides the ability to deliver a therapeutic molecule directly to the apical surface of the epithelium, by targeting the transcytotic receptor with an appropriate ligand. Thus, the highest concentration of the therapeutic molecule will be at the apical surface, where it can have the greatest therapeutic effect.

2006022, Oct 12, 2006

Jun 20, 2006

11/455791

Assem Ziady - Cleveland OH, US
Pamela Davis - Cleveland OH, US
Thomas Ferkol - Cleveland OH, US
Alfred Malouf - Cleveland OH, US

CASE WESTERN RESERVE UNIVERSITY - Cleveland OH

A61K 48/00, A61K 38/54, A61K 9/127

424450000, 514012000, 514044000

Serpin enzyme complex receptors are used as targets for therapeutic drugs in the lungs and brain tissue. any lung or brain disease and any therapeutic drug can be targeted to the lung or brain by use of ligands which specifically bind to the receptors. Complexes for delivery may include proteins, pharmacological agents, or nucleic acids, as well as carrier molecules, and ligands for the receptors. The ligands can be coupled directly to the therapeutic agent or to a carrier molecule which binds to the therapeutic agent.

6287817, Sep 11, 2001

Apr 26, 2000

9/559393

Pamela B. Davis - Cleveland Heights OH
Thomas Ferkol - Concord OH
Elizabeth Eckman - Ponte Vedra Beach FL
John Schreiber - Gates Mills OH
John M. Luk - South Horizons, HK

Case Western Reserve University - Cleveland OH

C12P 2104, C12Q 168, A61K 3800, C07H 2102

435 697

A protein conjugate consisting of antibody directed at the pIgR and A. sub. 1 AT can be transported specifically from the basolateral surface of epithelial cells to the apical surface. This approach provides us with the ability to deliver a therapeutic protein directly to the apical surface of the epithelium, by targeting the pIgR with an appropriate ligand. Thus, the highest concentration of the antiprotease will be at the apical surface, where it can do the greatest good in accelerating the inflammatory response.

2009011, May 7, 2009

Jun 2, 2006

11/916410

Pamela B. Davis - Cleveland Heights OH, US

A61K 31/4439, A61K 31/426, A61K 31/421, A61K 31/41

514342, 514365, 514360, 514369, 514376

A method of treating a subject with a cystic fibrosis related disorder includes administering a therapeutically effective amount of at least one PPARγ agonist or a derivative thereof.